Follow-Up of Study Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Vaccine
Both
Vaccine
Trial Information
Follow-Up of Study Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents
This protocol aims to provide long-term follow-up and continued use of research specimens of
patients previously enrolled on gene transfer or other immunotherapy studies at the National
Cancer Institute. Subjects will undergo an annual health history for up to 15 years.
Inclusion Criteria
- INCLUSION CRITERIA:
Subjects who received poxviral vectors (vaccinia and/or fowlpox) or other vaccines
utilizing gene transfer or any other immunotherapeutic agent through an LTIB affiliated
trial at the National Cancer Institute. These studies include (but are not limited to):
00-C-0137, 00-C-0154, 02-C-0218, 03-C-0176, 04-C-0167, 04-C-0246, 05-C-0017, 05-C-0167,
05-C-0229, 07-C-0106, 07-C-0107, 07-C-0188, 08-C-0166, 09-C-0101 and 11-C-0225. Upon
termination of the above protocols, available stored specimens obtained in each of the
protocols listed above will be transferred to this protocol for future research use.
EXCLUSION CRITERIA:
Patients unwilling to participate. (Please note, patients may participate in this
protocol and, at the same time, participate in an active treatment or continuing care
study.)
Type of Study:
Observational
Study Design:
N/A
Principal Investigator
James L Gulley, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
National Cancer Institute (NCI)
Authority:
United States: Federal Government
Study ID:
040274
NCT ID:
NCT00451022
Start Date:
September 2004
Completion Date:
Related Keywords:
- Vaccine
- Fowlpox
- Vaccinia
- PSA
- CEA
- MUC-1
- Gene Therapy
- Long Term Survivor
- Research Specimen
Name | Location |
|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda, Maryland 20892 |
